BRPI0517061A - formulação lipossomal de bortezomib (ps-341) - Google Patents
formulação lipossomal de bortezomib (ps-341)Info
- Publication number
- BRPI0517061A BRPI0517061A BRPI0517061-3A BRPI0517061A BRPI0517061A BR PI0517061 A BRPI0517061 A BR PI0517061A BR PI0517061 A BRPI0517061 A BR PI0517061A BR PI0517061 A BRPI0517061 A BR PI0517061A
- Authority
- BR
- Brazil
- Prior art keywords
- liposomes
- bortezomib
- liposomal formulation
- boronic acid
- liposome
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7024—Esters of saccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
FORMULAçãO LIPOSSOMAL DE BORTEZOMIB (PS-341 ). A presente invenção refere-se a uma composição de lipossoma compreendendo lipossomas tendo o composto de peptídeo ácido borónico, inibidor de protease, bortezomib incluído nos lipossomas. O composto de ácido borónico é incluído nos lipossomas na forma de um éster de boronato, subseqúente à interação com um poliol incluído em lipossoma. Em uma concretização, os lipossomas possuem um revestimento externo de cadeias poliméricas hidrofílicas e são usados para tratar um tumor sólido em um individuo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US62521604P | 2004-11-05 | 2004-11-05 | |
PCT/US2005/039972 WO2006052733A1 (en) | 2004-11-05 | 2005-11-04 | Liposomal formulation of bortezomib (ps-341) |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0517061A true BRPI0517061A (pt) | 2008-09-30 |
Family
ID=35947260
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0517061-3A BRPI0517061A (pt) | 2004-11-05 | 2005-11-04 | formulação lipossomal de bortezomib (ps-341) |
BRPI0517668-9A BRPI0517668A (pt) | 2004-11-05 | 2005-11-04 | formulação lipossÈmica de ácidos borÈnicos de peptìdeo |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0517668-9A BRPI0517668A (pt) | 2004-11-05 | 2005-11-04 | formulação lipossÈmica de ácidos borÈnicos de peptìdeo |
Country Status (21)
Country | Link |
---|---|
US (2) | US20060159736A1 (pt) |
EP (2) | EP1807052A1 (pt) |
JP (2) | JP2008519041A (pt) |
KR (2) | KR20070085644A (pt) |
CN (2) | CN101094648A (pt) |
AR (1) | AR051759A1 (pt) |
AU (2) | AU2005304881A1 (pt) |
BR (2) | BRPI0517061A (pt) |
CA (2) | CA2586354A1 (pt) |
CR (1) | CR9168A (pt) |
EA (1) | EA200701005A1 (pt) |
IL (1) | IL182967A0 (pt) |
MX (2) | MX2007005499A (pt) |
NI (1) | NI200700120A (pt) |
NO (1) | NO20072830L (pt) |
NZ (2) | NZ554950A (pt) |
PE (1) | PE20061135A1 (pt) |
TW (1) | TW200618820A (pt) |
UY (1) | UY29191A1 (pt) |
WO (2) | WO2006052734A1 (pt) |
ZA (1) | ZA200705017B (pt) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1932517A3 (en) * | 2006-12-11 | 2008-07-16 | Universiteit Utrecht Holding B.V. | Liposomes containing a polyphenol derivative such as caffeic acid and a method of post-loading thereof |
WO2009047639A2 (en) * | 2007-07-23 | 2009-04-16 | Keimyung University Industry Academic Cooperation Foundation | Epicatechin deficient green tea |
US7442830B1 (en) | 2007-08-06 | 2008-10-28 | Millenium Pharmaceuticals, Inc. | Proteasome inhibitors |
MY161991A (en) * | 2007-08-06 | 2017-05-31 | Millennium Pharm Inc | Proteasome inhibitors |
KR20100095507A (ko) * | 2007-08-21 | 2010-08-31 | 알자 코퍼레이션 | 보론산 화합물의 생체내 투여를 위한 리포좀 조성물 |
MX2010002101A (es) * | 2007-08-21 | 2010-03-26 | Alza Corp | Formulaciones de liposomas de compuestos de acido boronico. |
MX2010013642A (es) | 2008-06-17 | 2010-12-21 | Millennium Pharm Inc | Compuestos de ester boronato y composiciones farmaceuticas de los mismos. |
KR100918776B1 (ko) * | 2009-04-20 | 2009-09-24 | 계명대학교 산학협력단 | 폴리에틸렌 글리콜과 갈레이트 카테킨을 이용한 혈당상승 억제 조성물 |
JP5848127B2 (ja) | 2008-08-13 | 2016-01-27 | カリフォルニア インスティテュート オブ テクノロジー | 担体ナノ粒子ならびに関連する組成物、方法およびシステム |
US8263578B2 (en) | 2010-03-18 | 2012-09-11 | Innopharma, Inc. | Stable bortezomib formulations |
RU2529800C2 (ru) * | 2010-03-18 | 2014-09-27 | ИННОФАРМА, Инк. | Стабильные составы бортезомиба |
RS60310B1 (sr) | 2010-08-10 | 2020-07-31 | Rempex Pharmaceuticals Inc | Ciklični derivati estra boronske kiseline, postupak za pripremu injihove terapeutske upotrebe |
IT1403157B1 (it) | 2010-12-01 | 2013-10-04 | Elbi Int Spa | Macchina lavatrice con rilevazione delle vibrazioni della vasca o camera di lavaggio. |
AU2012223210B2 (en) * | 2011-03-02 | 2016-12-22 | Board Of Regents Of The University Of Texas System | Vesicle compositions |
CN102784114B (zh) * | 2011-05-14 | 2016-03-02 | 山东新时代药业有限公司 | 一种硼替佐米冻干粉针及其制备方法 |
AU2013360302C1 (en) | 2012-12-12 | 2019-01-24 | Temple University - Of The Commonwealth System Of Higher Education | Compositions and methods for treatment of cancer |
US9642869B2 (en) | 2013-01-04 | 2017-05-09 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
US9241947B2 (en) | 2013-01-04 | 2016-01-26 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
US9132097B2 (en) | 2013-03-01 | 2015-09-15 | California Institute Of Technology | Nanoparticles stabilized with nitrophenylboronic acid compositions |
US9468681B2 (en) | 2013-03-01 | 2016-10-18 | California Institute Of Technology | Targeted nanoparticles |
WO2015002078A1 (ja) | 2013-07-03 | 2015-01-08 | 日本化薬株式会社 | ボロン酸化合物の新規製剤 |
CN111116622A (zh) * | 2014-02-03 | 2020-05-08 | 俄亥俄州创新基金会 | 硼酸酯和其药物制剂 |
EP3139930A4 (en) | 2014-05-05 | 2018-01-17 | Rempex Pharmaceuticals, Inc. | Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof |
HUE046836T2 (hu) | 2014-05-05 | 2020-03-30 | Rempex Pharmaceuticals Inc | Boronát sók szintézise és alkalmazásuk |
CN106459096B (zh) | 2014-05-19 | 2019-03-08 | 莱姆派克斯制药公司 | 硼酸衍生物及其治疗用途 |
KR102509950B1 (ko) | 2014-05-20 | 2023-03-14 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | 일차 암 치료법 후 사용하기 위한 붕소-함유 프로테아좀 저해제 |
EA201692301A1 (ru) | 2014-07-01 | 2017-06-30 | Ремпекс Фармасьютикалз, Инк. | Производные бороновой кислоты и их терапевтическое применение |
WO2016081297A1 (en) | 2014-11-18 | 2016-05-26 | Rempex Pharmaceuticals, Inc. | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
US20180051041A1 (en) | 2015-03-17 | 2018-02-22 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
JP6715265B2 (ja) * | 2015-05-04 | 2020-07-01 | フェルザンティス アーゲーVersantis Ag | 膜内外pH勾配ベシクルを調製する方法 |
CN108135916B (zh) * | 2015-06-19 | 2022-01-28 | 北京科辉智药生物科技有限责任公司 | 手性特异性含硼化合物及其在治疗癌症或淀粉样变性中的应用 |
WO2017003668A1 (en) | 2015-07-01 | 2017-01-05 | California Institute Of Technology | Cationic mucic acid polymer-based delivery systems |
CN104958768A (zh) * | 2015-07-17 | 2015-10-07 | 中国科学院长春应用化学研究所 | 一种葡聚糖-硼替佐米键合药及其制备方法 |
US11135309B2 (en) * | 2015-08-14 | 2021-10-05 | The Regents Of The University Of California | Poly(vinyl alcohol) nanocarriers |
EP3478693B1 (en) | 2016-06-30 | 2021-07-21 | Qpex Biopharma, Inc. | Boronic acid derivatives and therapeutic uses thereof |
US10583083B1 (en) * | 2016-08-10 | 2020-03-10 | Verily Life Sciences Llc | ROS-responsive multilamellar liposomal vesicles for targeting inflammatory macrophages |
WO2018073790A1 (en) | 2016-10-20 | 2018-04-26 | Pfizer Inc. | Therapeutic particles with peptide boronic acid or boronate ester compounds and methods of making and using same |
US11964050B2 (en) * | 2017-07-24 | 2024-04-23 | Pharmosa Biopharm Inc. | Liposome compositions comprising weak acid drugs and uses thereof |
IL273551B2 (en) | 2017-10-11 | 2024-02-01 | Qpex Biopharma Inc | Boronic acid derivatives and their synthesis |
CN110540547A (zh) | 2018-05-28 | 2019-12-06 | 秦艳茹 | 一种肽硼酸酯类化合物的合成与用途 |
CN109045272A (zh) * | 2018-08-01 | 2018-12-21 | 厦门市壳聚糖生物科技有限公司 | 一种硼替佐米磷脂复合物及其制备方法与应用 |
EP4041246A4 (en) * | 2019-10-07 | 2023-11-01 | Cornell University | ANTIMICROBIAL AND ANTIVIRAL EFFECTS OF ALKYL-BORONIC ACIDS C2-C7 |
US20240173374A1 (en) * | 2021-02-25 | 2024-05-30 | Ohio State Innovation Foundation | Liposomal formulations of boronic acid containing active agents |
CN112915094A (zh) * | 2021-03-26 | 2021-06-08 | 东南大学 | 一种硼替佐米脂质体制剂的制备方法 |
WO2023220641A2 (en) | 2022-05-11 | 2023-11-16 | Juno Therapeutics, Inc. | Methods and uses related to t cell therapy and production of same |
WO2023220655A1 (en) | 2022-05-11 | 2023-11-16 | Celgene Corporation | Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy |
WO2024097905A1 (en) | 2022-11-02 | 2024-05-10 | Celgene Corporation | Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5736155A (en) * | 1984-08-08 | 1998-04-07 | The Liposome Company, Inc. | Encapsulation of antineoplastic agents in liposomes |
US5077056A (en) * | 1984-08-08 | 1991-12-31 | The Liposome Company, Inc. | Encapsulation of antineoplastic agents in liposomes |
US4885172A (en) * | 1985-06-26 | 1989-12-05 | The Liposome Company, Inc. | Composition for targeting, storing and loading of liposomes |
US5047245A (en) * | 1985-07-26 | 1991-09-10 | The Liposome Company, Inc. | Novel composition for targeting, storing and loading of liposomes |
US5252263A (en) * | 1986-06-16 | 1993-10-12 | The Liposome Company, Inc. | Induction of asymmetry in vesicles |
IL91664A (en) * | 1988-09-28 | 1993-05-13 | Yissum Res Dev Co | Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release |
US6132763A (en) * | 1988-10-20 | 2000-10-17 | Polymasc Pharmaceuticals Plc | Liposomes |
US5013556A (en) * | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5620689A (en) * | 1989-10-20 | 1997-04-15 | Sequus Pharmaceuuticals, Inc. | Liposomes for treatment of B-cell and T-cell disorders |
AU660288B2 (en) * | 1990-07-31 | 1995-06-22 | Transave, Inc. | Accumulation of amino acids and peptides into liposomes |
US5395619A (en) * | 1993-03-03 | 1995-03-07 | Liposome Technology, Inc. | Lipid-polymer conjugates and liposomes |
US6180134B1 (en) * | 1993-03-23 | 2001-01-30 | Sequus Pharmaceuticals, Inc. | Enhanced ciruclation effector composition and method |
US6326353B1 (en) * | 1993-03-23 | 2001-12-04 | Sequus Pharmaceuticals, Inc. | Enhanced circulation effector composition and method |
US6083903A (en) * | 1994-10-28 | 2000-07-04 | Leukosite, Inc. | Boronic ester and acid compounds, synthesis and uses |
US6214388B1 (en) * | 1994-11-09 | 2001-04-10 | The Regents Of The University Of California | Immunoliposomes that optimize internalization into target cells |
US5972379A (en) * | 1995-02-14 | 1999-10-26 | Sequus Pharmaceuticals, Inc. | Liposome composition and method for administering a quinolone |
EP0825852B1 (en) * | 1995-04-18 | 2004-07-07 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Liposome drug-loading method and composition |
US6224903B1 (en) * | 1996-10-11 | 2001-05-01 | Sequus Pharmaceuticals, Inc. | Polymer-lipid conjugate for fusion of target membranes |
US6056973A (en) * | 1996-10-11 | 2000-05-02 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method of preparation |
WO1998016201A1 (en) * | 1996-10-11 | 1998-04-23 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method |
WO1998017256A1 (en) * | 1996-10-22 | 1998-04-30 | Dmitri Kirpotin | Compound-loaded liposomes and methods for their preparation |
US6831057B2 (en) * | 1997-10-28 | 2004-12-14 | The University Of North Carolina At Chapel Hill | Use of NF-κB inhibition in combination therapy for cancer |
US6051251A (en) * | 1997-11-20 | 2000-04-18 | Alza Corporation | Liposome loading method using a boronic acid compound |
KR100679906B1 (ko) * | 1998-09-16 | 2007-02-07 | 알자 코포레이션 | 리포솜-엔트랩된 토포이소머라제 억제제 |
CA2379060A1 (en) * | 1999-07-14 | 2001-01-25 | Alza Corporation | Neutral lipopolymer and liposomal compositions containing same |
AU1658401A (en) * | 1999-11-19 | 2001-05-30 | Topgene, Inc. | Boron compounds and complexes as anti-inflammatory agents |
EP3078667B1 (en) * | 2001-01-25 | 2018-11-21 | The United States of America, represented by the Secretary, Department of Health and Human Services | Formulation of boronic acid compounds |
US20060084592A1 (en) * | 2002-09-09 | 2006-04-20 | Trigen Limited | Peptide boronic acid inhibitors |
CA2504933C (en) * | 2002-11-06 | 2012-10-16 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for treating cancer using proteasome inhibitors |
-
2005
- 2005-10-25 TW TW094137236A patent/TW200618820A/zh unknown
- 2005-11-02 PE PE2005001284A patent/PE20061135A1/es not_active Application Discontinuation
- 2005-11-04 CA CA002586354A patent/CA2586354A1/en not_active Abandoned
- 2005-11-04 US US11/267,076 patent/US20060159736A1/en not_active Abandoned
- 2005-11-04 AU AU2005304881A patent/AU2005304881A1/en not_active Abandoned
- 2005-11-04 AR ARP050104638A patent/AR051759A1/es unknown
- 2005-11-04 JP JP2007540071A patent/JP2008519041A/ja not_active Withdrawn
- 2005-11-04 CN CNA2005800457552A patent/CN101094648A/zh active Pending
- 2005-11-04 KR KR1020077012434A patent/KR20070085644A/ko not_active Application Discontinuation
- 2005-11-04 CA CA002586348A patent/CA2586348A1/en not_active Abandoned
- 2005-11-04 BR BRPI0517061-3A patent/BRPI0517061A/pt not_active IP Right Cessation
- 2005-11-04 AU AU2005304880A patent/AU2005304880A1/en not_active Abandoned
- 2005-11-04 MX MX2007005499A patent/MX2007005499A/es unknown
- 2005-11-04 EP EP05821699A patent/EP1807052A1/en not_active Withdrawn
- 2005-11-04 BR BRPI0517668-9A patent/BRPI0517668A/pt not_active IP Right Cessation
- 2005-11-04 NZ NZ554950A patent/NZ554950A/en not_active IP Right Cessation
- 2005-11-04 EP EP05824137A patent/EP1807053A1/en not_active Withdrawn
- 2005-11-04 WO PCT/US2005/039973 patent/WO2006052734A1/en active Application Filing
- 2005-11-04 MX MX2007005497A patent/MX2007005497A/es unknown
- 2005-11-04 WO PCT/US2005/039972 patent/WO2006052733A1/en active Application Filing
- 2005-11-04 NZ NZ554951A patent/NZ554951A/en not_active IP Right Cessation
- 2005-11-04 JP JP2007540070A patent/JP2008519040A/ja not_active Withdrawn
- 2005-11-04 EA EA200701005A patent/EA200701005A1/ru unknown
- 2005-11-04 KR KR1020077012432A patent/KR20070085642A/ko not_active Application Discontinuation
- 2005-11-04 US US11/267,794 patent/US20060153907A1/en not_active Abandoned
- 2005-11-04 CN CNA2005800457618A patent/CN101094649A/zh active Pending
- 2005-11-04 UY UY29191A patent/UY29191A1/es unknown
-
2007
- 2007-05-03 IL IL182967A patent/IL182967A0/en unknown
- 2007-05-04 NI NI200700120A patent/NI200700120A/es unknown
- 2007-06-04 ZA ZA200705017A patent/ZA200705017B/xx unknown
- 2007-06-04 NO NO20072830A patent/NO20072830L/no not_active Application Discontinuation
- 2007-06-05 CR CR9168A patent/CR9168A/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
KR20070085642A (ko) | 2007-08-27 |
MX2007005497A (es) | 2007-09-21 |
WO2006052734A1 (en) | 2006-05-18 |
CN101094649A (zh) | 2007-12-26 |
UY29191A1 (es) | 2006-01-31 |
CN101094648A (zh) | 2007-12-26 |
NZ554950A (en) | 2010-12-24 |
US20060159736A1 (en) | 2006-07-20 |
AU2005304880A1 (en) | 2006-05-18 |
NZ554951A (en) | 2010-12-24 |
EA200701005A1 (ru) | 2007-10-26 |
AR051759A1 (es) | 2007-02-07 |
EP1807053A1 (en) | 2007-07-18 |
AU2005304881A1 (en) | 2006-05-18 |
CA2586348A1 (en) | 2006-05-18 |
JP2008519041A (ja) | 2008-06-05 |
KR20070085644A (ko) | 2007-08-27 |
JP2008519040A (ja) | 2008-06-05 |
NI200700120A (es) | 2008-05-15 |
EP1807052A1 (en) | 2007-07-18 |
WO2006052733A1 (en) | 2006-05-18 |
ZA200705017B (en) | 2008-09-25 |
NO20072830L (no) | 2007-07-24 |
IL182967A0 (en) | 2007-08-19 |
TW200618820A (en) | 2006-06-16 |
PE20061135A1 (es) | 2006-10-20 |
CA2586354A1 (en) | 2006-05-18 |
US20060153907A1 (en) | 2006-07-13 |
CR9168A (es) | 2008-11-24 |
MX2007005499A (es) | 2007-09-21 |
BRPI0517668A (pt) | 2008-10-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0517061A (pt) | formulação lipossomal de bortezomib (ps-341) | |
ECSP109983A (es) | Formulaciones de liposomas de compuestos de acido boronico | |
UY27740A1 (es) | Nuevos compuestos | |
CL2012003229A1 (es) | Formulación farmacéutica para aplicación tópica en la piel que comprende una emulsión de aceite en agua y el compuesto (r)-3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]propanonitrilo, inhibidor de jak1/jak2; método para tratar un trastorno de la piel; y su uso en el tratamiento de un trastorno de la piel. | |
AR048878A1 (es) | Composiciones topicas de metadona y metodos para usarlas | |
BRPI0409319B8 (pt) | composto, composição farmacêutica, forma de dosagem unitária, e, uso de um composto | |
BR0114713A (pt) | Formulação lipossÈmica de mitoxantrona | |
CL2012003281A1 (es) | Uso de compuestos específicos estimuladores y/o activadores de sgc; formulacion farmaceutica que comprende dichos compuestos; kit que comprende los compuestos, y uso para la prevencion y/o tratamiento de la esclerosis sistematica. | |
WO2004060315A3 (en) | Stable topical drug delivery compositions | |
ATE411006T1 (de) | Liposomale anordnung für die therapeutische und/oder diagnostische anwendung | |
AR090349A1 (es) | Terapia de combinacion para trastornos proliferativos, kit y uso | |
MXPA04001034A (es) | Compuestos para sanar heridas y en contra de envejecimiento. | |
BRPI0207961B8 (pt) | uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos. | |
CY1108700T1 (el) | Συνθεσεις απελευθερωσης φαρμακου εστερα αλφα-υδροξυ οξεος και μεθοδοι χρησης | |
AR054833A1 (es) | Formas de dosificacion de liberacion retardada oral altamemte biodisponibles de succinato de o-desmetilvenlafaxina | |
FR2870125B1 (fr) | Formulation du type spot-on utile en cosmetologie et en dermatologie | |
ECSP066970A (es) | Preparaciones tópicas que contienen ambroxol | |
CA2571796A1 (en) | Cosmetic compositions and methods containing a tanning agent and liposome-enscapsulated ursolic acid | |
ATE432111T1 (de) | Transparente kosmetische oder dermatologische formulierung | |
NI201000047A (es) | Uso de 3, 11b-cis-dihidrotetrabenzina en el tratamiento de la esclerosis múltiple y la mielitis autoinmunitaria. | |
BR112012022243A8 (pt) | Uso de um inibidor de autofagia baseado em tioxantona e de um composto indutor de autofagia para terapia de câncer, composição farmacêutica e kit farmacêutico | |
BRPI0518554A2 (pt) | uso de um inibidor de pde3 | |
UY31826A (es) | Compuesto peptídico y su uso | |
HK1087010A1 (en) | Use of a composition comprising vitamin k1 oxide or a derivative thereof for the treatment and/or the prevention of mammal dermatological lesions | |
SE0301884D0 (sv) | New use III |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AO NAO RECOLHIMENTO DA 7A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2211 DE 21/05/2013. |